Pembrolizumab in an HIV-infected Patient with Glioblastoma

Overview

Journal Immunotherapy

Specialties Allergy & Immunology
Pharmacology

Date 2024 Jun 18

PMID 38889068

Authors

Carlen A Yuen

Silin Bao

Melike Pekmezci

Fan Mo

Xiao-Tang Kong

Affiliations

Soon will be listed here.

Abstract

Persons living with human immunodeficiency virus (PLWH) carry increased risk for developing malignancies, including glioblastoma. Despite extensive investigations, both human immunodeficiency virus (HIV) and glioblastoma are incurable. Treatment for a patient with combined glioblastoma and HIV remains an unexplored need. Preliminary evidence suggests that immunotherapy may be effective for the simultaneous treatment of both HIV and cancer by reversing HIV latency and T cell exhaustion. We present a case of glioblastoma in a PLWH who was treated with pembrolizumab. Treatment was well tolerated and safe with a mixed response. Our patient did not develop any opportunistic infections, immune-related adverse events, or worsening of his immunodeficiency. To our knowledge, this is the first reported case of a PLWH and glioblastoma treated with immunotherapy.

References

Rodrigues L, Camacho A, Spohr T . Secondary glioblastoma metastasis outside the central nervous system in a young HIV-infected patient. Ther Adv Med Oncol. 2020; 12:1758835920923432. PMC: 7238297. DOI: 10.1177/1758835920923432. View

Rasmussen T, Rajdev L, Rhodes A, Dantanarayana A, Tennakoon S, Chea S . Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. Clin Infect Dis. 2021; 73(7):e1973-e1981. PMC: 8492152. DOI: 10.1093/cid/ciaa1530. View

Ferrara R, Signorelli D, Proto C, Prelaj A, Garassino M, Lo Russo G . Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. Transl Lung Cancer Res. 2021; 10(6):2955-2969. PMC: 8264338. DOI: 10.21037/tlcr-20-636. View

Woroniecka K, Fecci P . T-cell exhaustion in glioblastoma. Oncotarget. 2018; 9(82):35287-35288. PMC: 6219672. DOI: 10.18632/oncotarget.26228. View

Choy W, Lagman C, Lee S, Bui T, Safaee M, Yang I . Impact of Human Immunodeficiency Virus in the Pathogenesis and Outcome of Patients with Glioblastoma Multiforme. Brain Tumor Res Treat. 2016; 4(2):77-86. PMC: 5114196. DOI: 10.14791/btrt.2016.4.2.77. View

Valdez M, Lu V, Kim E, Rivas S, Govindarajan V, Ivan M . Glioblastoma multiforme in patients with human immunodeficiency virus: an integrated review and analysis. J Neurooncol. 2022; 159(3):571-579. DOI: 10.1007/s11060-022-04095-4. View

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Hatano H . Immune activation and HIV persistence: considerations for novel therapeutic interventions. Curr Opin HIV AIDS. 2013; 8(3):211-6. PMC: 4041488. DOI: 10.1097/COH.0b013e32835f9788. View

Burke M, Kluger H, Golden M, Heller K, Hoos A, Sznol M . Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma. J Clin Oncol. 2011; 29(32):e792-4. DOI: 10.1200/JCO.2011.36.9199. View

10.

Dahabieh M, Battivelli E, Verdin E . Understanding HIV latency: the road to an HIV cure. Annu Rev Med. 2015; 66:407-21. PMC: 4381961. DOI: 10.1146/annurev-med-092112-152941. View

11.

Scully E, Rutishauser R, Simoneau C, Delagreverie H, Euler Z, Thanh C . Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. Ann Oncol. 2018; 29(10):2141-2142. PMC: 6225895. DOI: 10.1093/annonc/mdy259. View

12.

Luzuriaga K, Gay H, Ziemniak C, Sanborn K, Somasundaran M, Rainwater-Lovett K . Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med. 2015; 372(8):786-8. PMC: 4440331. DOI: 10.1056/NEJMc1413931. View

13.

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W . Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015; 16(15):e534-e542. PMC: 4638131. DOI: 10.1016/S1470-2045(15)00088-1. View

14.

Corrigan K, Wall K, Bartlett J, Suneja G . Cancer disparities in people with HIV: A systematic review of screening for non-AIDS-defining malignancies. Cancer. 2019; 125(6):843-853. PMC: 6488220. DOI: 10.1002/cncr.31838. View

15.

Suneja G, Coghill A . Cancer care disparities in people with HIV in the United States. Curr Opin HIV AIDS. 2016; 12(1):63-68. PMC: 6424354. DOI: 10.1097/COH.0000000000000320. View

16.

Wu M, Zheng X, Zhang Y, Song J, Zhao J . Camrelizumab for cancers in patients living with HIV: one-single center experience. AIDS Res Ther. 2023; 20(1):23. PMC: 10108516. DOI: 10.1186/s12981-023-00518-y. View

17.

de Oliveira V, Gomes T, Lima Ferreira L, Damian M, Silva V, Araujo J . Glioblastoma Multiforme in an HIV-Infected Patient: An Unexpected Diagnosis. J Int Assoc Provid AIDS Care. 2014; 13(5):411-3. DOI: 10.1177/2325957414536230. View

18.

Ostios-Garcia L, Faig J, Leonardi G, Adeni A, Subegdjo S, Lydon C . Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. J Thorac Oncol. 2018; 13(7):1037-1042. DOI: 10.1016/j.jtho.2018.03.031. View

19.

Swindells S, Andrade-Villanueva J, Richmond G, Rizzardini G, Baumgarten A, Masia M . Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020; 382(12):1112-1123. DOI: 10.1056/NEJMoa1904398. View

20.

Eun Y, Kim I, Sun J, Lee J, Cha H, Koh E . Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep. 2019; 9(1):14039. PMC: 6773778. DOI: 10.1038/s41598-019-50574-6. View